Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook

TEVA PHARMACEUTICAL INDUSTRIES LTD

2025-Q1 EPS reported $0.18 revenue$3,891,000,000

Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).
Key innovative products grew ~39% YoY: AUSTEDO $411M (+39%), AJOVY $139M (+26%), UZEDY $39M.
FY2025 guidance raised: Non-GAAP EPS $2.45-$2.65 (midpoint +$0.10), Non-GAAP op income $4.3-$4.6B (+$200M at low end).
Generics grew in all regions (U.S. +5%, Europe +1%, Intl +2% in local currency).
On track for 30% operating margin by 2027; announces $700M net savings program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.